BiolineRX raises $24m in Nasdaq offering
The Yokne'am incubator focuses on medical device start-ups
The Naiot Venture Accelerator was one of the last government incubators to be privatized. However, de-facto the incubator has been run like a private company for years and many claim it was the model for the government privatization program.
If the success of an incubator start-up venture is its subsequent ability to raise investment funds then most Naiot graduates are successes. Naiot CEO Haim Eliash said, "80% of the companies that have graduated up until today raised funds of $500,000 or more. "We try very hard to see that the funds are not only raised from Ofer Hi-Tech but bring in at least one more partner to fix the company's value"
Successful graduates of the Naiot Venture Accelerator include: cardiovascular balloon developer Angioslide, biofunctional ingredients supplements company Enzymotec Ltd., CorAssist Cardiovascular Ltd., catheter device developer Endocross Ltd., retractor maker EZ Surgical Ltd., stem cell company Multi Gene Vascular Systems Ltd. (MGVS), and Rimon Medical Ltd., which was sold to Boston Scientific for $135 million.
The Naiot Venture accelerator is owned by Ofer Hi-Tech Group the venture capital investment arm of the Ofer family and Udi Angel, and it only officially became a private company several months ago. According to Assif Stoffman a partner with Ofer Hi-Tech, a member of Naiot's board of directors and a former CEO of the incubator, the pre-privatization management structure suited Ofer Hi-Tech.
He said, We loved the government model. We allocated supplementary funding and the companies paid us back with royalties."
He added, "We did not build companies designed for a huge exit, but medium sized companies that quickly reached sales revenue and paid the incubator handsome royalties."
In effect, Naiot is the seed fund of Ofer HiTech.
In the medical device sector investments are varied and 20-30% of investments in software,
You comment was recieved and soon will be published.
Load more comments
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.